LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.21

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.2

Максимум

1.22

Ключови измерители
By Trading Economics
Приходи	17M -26M
EPS	-0.43
Марж на печалбата	-2,190.837
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+143.9% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-26M 76M
Предишно отваряне	1.21
Предишно затваряне	1.21

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.12.2025 г., 17:29 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19.12.2025 г., 16:47 ч. UTC

Значими двигатели на пазара

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19.12.2025 г., 16:10 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

20.12.2025 г., 19:00 ч. UTC

Печалби

Consumer Confidence, Economic Activity Data, and a Short Trading Week for Christmas -- Barrons.com

19.12.2025 г., 22:33 ч. UTC

Печалби

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19.12.2025 г., 22:19 ч. UTC

Печалби

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19.12.2025 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19.12.2025 г., 21:44 ч. UTC

Печалби

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19.12.2025 г., 21:38 ч. UTC

Печалби

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19.12.2025 г., 21:00 ч. UTC

Пазарно говорене

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19.12.2025 г., 20:23 ч. UTC

Пазарно говорене

Oil Futures End Down Week on Up Note -- Market Talk

19.12.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19.12.2025 г., 18:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19.12.2025 г., 18:00 ч. UTC

Пазарно говорене

Печалби

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19.12.2025 г., 17:41 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19.12.2025 г., 17:24 ч. UTC

Пазарно говорене

Печалби

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

19.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

19.12.2025 г., 16:29 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19.12.2025 г., 16:20 ч. UTC

Придобивния, сливания и поглъщания

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19.12.2025 г., 16:19 ч. UTC

Придобивния, сливания и поглъщания

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19.12.2025 г., 16:18 ч. UTC

Придобивния, сливания и поглъщания

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19.12.2025 г., 16:16 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

19.12.2025 г., 16:16 ч. UTC

Пазарно говорене

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19.12.2025 г., 16:05 ч. UTC

Придобивния, сливания и поглъщания

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19.12.2025 г., 16:04 ч. UTC

Придобивния, сливания и поглъщания

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19.12.2025 г., 15:37 ч. UTC

Пазарно говорене

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19.12.2025 г., 15:21 ч. UTC

Пазарно говорене

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19.12.2025 г., 15:09 ч. UTC

Пазарно говорене

Gold Flat But Set for Weekly Gains -- Market Talk

19.12.2025 г., 15:09 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

143.9% нагоре

12-месечна прогноза

Среден 3 USD 143.9%

Висок 4 USD

Нисък 2 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.